Vergelijking

Ganirelix vs. Lanreotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

123246-29-7

108736-35-2

Molecuulmassa

1570.3 g/mol

1096.34 g/mol

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Ganirelix

Ganirelix competitively and reversibly binds the pituitary GnRH receptor, rapidly suppressing LH (and, less so, FSH) release — without the initial hormone 'flare' of GnRH agonists.

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Ganirelix	Lanreotid
Duitsland	Op recept	Op recept
Verenigde Staten	Op recept	Op recept

Volledige vermeldingen

Ganirelix

Volledige vermelding →

Lanreotid

Volledige vermelding →

Frequently asked questions

What is the difference between Ganirelix and Lanreotid?: Ganirelix is classified as "Onderzoek (overig)", while Lanreotid is classified as "Onderzoek (overig)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Ganirelix or Lanreotid?: The highest available evidence level is "Humane RCT" for Ganirelix and "Humane RCT" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Ganirelix and Lanreotid in Germany and the United States?: Duitsland: Ganirelix — Op recept, Lanreotid — Op recept. Verenigde Staten: Ganirelix — Op recept, Lanreotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Ganirelix

Lanreotid

Duitsland

Op recept

Verenigde Staten

Op recept

Frequently asked questions

What is the difference between Ganirelix and Lanreotid?

Ganirelix is classified as "Onderzoek (overig)", while Lanreotid is classified as "Onderzoek (overig)". Ganirelix: Ganirelix is a synthetic decapeptide and GnRH antagonist. In assisted reproduction (IVF) it prevents the premature LH surge during controlled ovarian stimulation. Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Ganirelix or Lanreotid?

The highest available evidence level is "Humane RCT" for Ganirelix and "Humane RCT" for Lanreotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Ganirelix and Lanreotid in Germany and the United States?

Duitsland: Ganirelix — Op recept, Lanreotid — Op recept. Verenigde Staten: Ganirelix — Op recept, Lanreotid — Op recept. These are factual summaries with source and review date on the individual pages.